Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
58.37
-0.41 (-0.70%)
Bozor ochiq: Aug 12, 2026, 3:02 PM EDT
57.40
-1.38 (-2.35%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Enliven Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton bilan kasallangan bemorlarga yordam berish uchun kichik molekulyar ingibitorlarni kashf qilish va ishlab chiqishga qaratilgan. Uning klinik dasturlari orasida surunkali miyeloid leykemiya bilan kasallangan kattalarni davolash uchun 1-faza klinik sinovlarida bo'lgan kichik molekulyar kinaza ingibitori ELVN-001; va markaziy asab tizimiga (MS) kirib boradigan va qaytarilmas inson epidermis o'sish omili retseptorlari 2 ingibitori ELVN-002 mavjud bo'lib, u 1-faza klinik sinovlarida mayda hujayrali o'pka saratonini (NSCLC) va boshqa HER2 mutatsiyasiga ega o'smalarni davolash uchun ishlatiladi. Kompaniya 2019 yilda tashkil etilgan va shtab-kvartirasi Kolorado shtatining Bouldr shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Damiette Smit | Vice President of Clinical Development |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Research Fellow |
| Mr. Anish Patel Pharm.D. | Co-Founder & COO |
| Mr. Benjamin Hohl | CFO & Head of Corporate Development |
| Mr. Richard A. Fair M.B.A. | CEO, President & Director |
| Mr. Samuel S. Kintz M.B.A. | Co-Founder & Head of Pipeline |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-05 | 8-K | elvn-20260805.htm |
| 2026-08-05 | 10-Q | elvn-20260630.htm |
| 2026-06-12 | 8-K | d152122d8k.htm |
| 2026-06-11 | 8-K | d202685d8k.htm |
| 2026-06-10 | 8-K | d152745d8k.htm |
| 2026-05-07 | 8-K | elvn-20260507.htm |
| 2026-05-07 | 10-Q | elvn-20260331.htm |
| 2026-04-27 | DEFA14A | d948532ddefa14a.htm |
| 2026-04-27 | DEF 14A | d948512ddef14a.htm |
| 2026-04-27 | ARS | d948538dars.pdf |